Abstract
Little is known of how anthracyclines are transported into the heart. Our previous kinetic study suggested saturable myocardial uptake of idarubicin. This study sought to determine the effects of temperature reduction and of doxorubicin coadministration on the transport process. In Langendorff-perfused rat hearts, a 0.5 mg dose of idarubicin was infused over 10 min. The outflow concentration-time curve as well as the residual amounts in cardiac tissue of idarubicin and its active metabolite idarubicinol were measured after temperature reduction (from 37 degrees C to 30 degrees C) and in the presence of doxorubicin (20 microM) in the perfusate. The outflow concentration-time profile of idarubicin was analyzed by a four-compartment model and simultaneous nonlinear regression. Doxorubicin significantly inhibited the Michaelis-Menten-like uptake process of idarubicin in the heart (50% decrease in Vmax), leading to a decreased net tissue uptake of idarubicin. Kinetic analysis of sensitivity to temperature reduction revealed a 2.6-fold increase in KM; however, this inhibition of idarubicin uptake was counterbalanced by a decrease in efflux rate. These data confirm the existence of a saturable myocardial uptake mechanism for idarubicin and might provide useful information for optimizing anthracycline dosage regiments.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
